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Abstract
Polycomb group (PcG) proteins are crucial for neural cancer stem cell (NCSC) self-renewal. However, the relative
expression levels of PcG genes in different subtypes of brain tumors, their prognostic role and their effects on cel-
lular pathways have not been investigated. For this purpose, we queried the Oncomine database and found that 4
PcG genes (EZH2, RBBP7, SUZ12, YY1) are specifically expressed in brain tumors. EZH2 expression increases with
tumor grade in adult and pediatric brain tumors, and is a poor prognostic factor. In glioblastoma, EZH2 inhibits dif-
ferentiation, and activates cancer-, cell cycle- and cellular movement-related genes. In keeping with previously pub-
lished data, our results suggest that EZH2 is both a prognostic factor and a promising therapy target in brain
tumors.
Findings
Central Nervous System (CNS) tumors occur at each
stage of life, and are therefore classified as embryonal,
pediatric and adult cancers [1-3]. Treatment and prog-
nosis are dependent on tumor histology. For pediatric
and adult CNS cancers, tumor grade is the main prog-
nostic factor [1,3].
Due to the lack of effective therapies for aggressive
CNS tumors, the identification of new targets and prog-
nostic indicators is warranted. Recent evidence shows
that, in addition to genetic changes, CNS tumors are
driven by epigenetic alterations, namely DNA methyla-
tion and histone post-translational modifications [4].
Polycomb group (PcG) genes are epigenetic effectors
involved in CNS development and cancer progression
[5]. PcG proteins are organized in polycomb repressive
complexes (PRCs). During development, PRCs catalyze
histone post-translational modifications and gene silen-
cing. The best characterized complexes are PRC1 and
PRC2. The latter mediates histone H3K27 methylation.
PRC1 binds to this chromatin modification and catalyzes
histone H2A ubiquitylation. PRCs silence lineage-speci-
fic genes in embryonic and adult stem cells (SCs) [5].
During brain development, PRCs are expressed in a
time- and region-specific manner, thereby orchestrating
SC proliferation and differentiation [6]. Each PRC iso-
form targets a different set of loci. This combinatorial
complexity affects the subtle balance between SC self-
renewal and differentiation [5].
Recent evidence indicates that most CNS tumors are
driven by a small population of CD133
+ neural cancer
stem cells (NCSC) [7]. These cells are resistant to con-
ventional chemotherapy [8,9] and are the only cells able
to initiate a tumor when injected into immunocompro-
mised mice [7]. In adition, CD133 is up-regulated in
high grade CNS tumors, and is a poor prognostic indi-
cator [10]. Targeting NCSCs could eradicate CNS
tumors [11,12]. However, most data in favor of the
NCSC hypothesis are derived from mouse and in vitro
studies. The role of NCSC in the clinical setting is still
elusive.
For their function in SC biology and cancer [5], PcG
genes are obvious candidates for NCSC-specific targeted
therapy. PcG targets are specifically silenced in brain
tumors [13]. and the PRC2 member EZH2 may be over-
xpressed in gliomas [14]. In addition, BMI1 copy num-
ber alteration is frequent in human gliomas [15]. BMI1
is a PRC1 component, essential for NCSC self-renewal
and tumorigenicity [16]. PcG genes are also involved in
CD133
+ glioma SC radioresistance [17].
In the present paper, we queried the Oncomine data-
base to systematically assess relative gene expression
levels of PcG genes in CNS tumors. Gene expression
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were collected from Oncomine database http://www.
oncomine.com. Data were from 34 independent studies.
We investigated gene expression profile of 21 PcG
genes: Pc, PH, RING and PSC homologs (PRC1); EED,
EZH2, SUZ12 (PRC2); YY (1 and 2), SCML1, SIRT,
L3MBTL2, RBBP. These genes have been selected based
on previously published lists [18,19]. We compared gene
expression in normal brain vs. cancer tissues, and in dif-
ferent histological subtypes.
To identify PcG targets inactivated in brain tumors,
we interrogated the following Oncomine categories:
“PcG target genes in human embryonic SCs” and “Top
10% downregulated genes in glioblastoma (Sun Brain)”.
We found 106 overlapping genes. Since these genes
were identified by the intersection of data from genes
that are silenced by PRC2 in human embryonic SCs and
from glioblastoma studies, these 106 overlapping genes
will be hereinafter called “PRC2 targets in brain
tumors”.
To identify genes expressed in association with EZH2,
coexpression data from 3 large studies (Beroukhim, Phil-
lips, Sun, 467 patients) were collected. We found 213
genes positively correlated to EZH2 (R > 0.70). These
genes will be called “EZH2-associated genes”.
All statistical values relative to this meta-analysis were
calculated as described by Chinnaiyan and colleagues
[20].
Table 1 summarizes differentially expressed PcG genes
in normal brain, brain tumors and specific tumor histolo-
gies. Surprisingly, some PRC1 components (BMI1, CBX2,
CBX7) were downreglated in glioblastoma compared to
normal brain. Other PRC1 members (CBX7, PCGF6)
were selectively expressed in lower grade gliomas. In con-
trast, the PRC2 components EZH2 and SUZ12 were
always overexpressed in tumors compared to normal
neural tissue. In addition, these 3 independent studies all
showed a highly significant correlation between EZH2
overexpression and gliomas. Moreover, EZH2 expression
significantly increased with tumor grade in both adult
and pediatric brain tumors (Figure 1A, B).
These results show that PRC2 genes may play a cru-
cial role in adult and pediatric brain tumors. BMI1
mRNA expression seems not to predict tumor progres-
s i o n .T h i ss e e m st ob ei nc o n t r a s tw i t hp r e v i o u se v i -
dence [16], showing thatB M I 1p r o t e i ns u s t a i n s
glioblastoma CSC self-renewal. However, BMI1 protein
and mRNA levels may not be directly correlated, and
many post-transcriptional modulations may explain this
discrepancy.
Table 1 Polycomb genes expression in normal brain and specific tumor histologies.
PRC GENE Category 1
(up-regulated)
Category 2
(down- regulated)
P value
1 BMI1 Normal Brain Glioblastoma 5.85 E-27
CBX2 Neural Stem Cell Glioblastoma 4.4 E-13
CBX7 Normal Brain Glioblastoma 2.2 E-27
Ganglioneur-oma/-oblastoma Neuroblastoma 2.4 E-7
PCGF1 Glioblastoma Astrocytoma 1.2 E-6
PCGF6 Astrocytoma/Oligodendroglioma Glioblastoma 4.0 E-6
PHC2 Astrocytoma/Glioblastoma Oligodendroglioma 1.4 E-7
YY1 Anaplastic Oligoastrocytoma Normal Brain 1.23 E-5
Medulloblastoma with Advanced Neural Differentiation Other hystologies 8.86 E-27
Oligodendroglioma Mixed Glioma 3.83 E-6
2, 3, 4 EZH2 Anaplastic Oligodendroglioma Normal Brain 1,12E-12
Anaplastic Astrocytoma Normal Brain 3,50E-13
Glioblastoma Normal Brain 2,56E-23
Neuroblastoma Ganglioneur-oma/-oblastoma 4,94E-08
Glioblastoma Astrocytoma/Ogligodendroglioma 1.64 E-5
RBBP7 Anaplastic Astrocytoma Normal Brain 6,0E-06
Anaplastic Oligodenroglioma Normal Brain 5,60E-08
SUZ 12 Anaplastic Oligodendroglioma Normal Brain 1.19 E-7
Atypical Theratoid/Rhabdoid Tumor Medulloblastoma 5.50 E-8
4 SIRT1 Neural Stem Cell Glioblastoma 9.4 E-13
Oligodendroglioma Glioblastoma Astrocytoma 1.9 E-11
Data derived from Oncomine database. Grading analyses were performed on 35 adult and 19 pediatric brain tumors. Survival analysis was performed on a total
of 97 glioblastoma patients.
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Page 2 of 6Since EZH2 is essential for NCSC self-renewal [12],
and due to our results showing that EZH2 is overex-
pressed in brain tumors, we investigated the prognostic
role of EZH2 in gliobalstoma. Two independent studies
showed a highly significant association between EZH2
overexpression and poorer 1 year- and 3 year-survival in
glioblastoma patients (Figure 1C, D). We identified a
significant and progressive (p = 4.4E
-7, odds ratio = 2.0)
pattern of PRC2 target gene silencing in gliomas (Figure
2A). In addition, a list of 52 PRC2 targets was downre-
gulated in poor prognosis-glioblastoma patients, and
predicted shorter 3-year survival (p = 4.2E
-6,o d d sr a t i o
= 2.2, additional file 1).
Our analysis suggests that glioma progression is asso-
ciated with EZH2 overexpression and PRC2 target gene
silencing. Thus, we investigated which pathways are co-
activated with EZH2, and which pathways are silenced
by PRC2. For these purposes, we compared two sets of
genes: PRC2 targets in glioma and EZH2-associated
genes. The latter category includes 213 genes positively
correlated with EZH2, identified in three large microar-
ray studies in brain tumors. Ingenuity pathway analysis
(IPA, Ingenuity® Systems, http://www.ingenuity.com of
EZH2-associated genes showed the following top cate-
gories: “Cancer” (4.6E
-14<p < 1.5E
-2), “Cell cycle”
(6.02E
-31<p < 1.5E
-2)a n d“Embryonic development”
(2.3E
-5<p < 1.5E
-2). Interestingly, when we compared
IPA for both EZH2-associated genes and PRC2 targets
in brain tumors, we found that the first gene set was
significantly enriched for Cell-cycle- Cancer-, and Cellu-
lar movement-associated genes, compared to PRC2 tar-
gets (Figure 2B). Gene categories significantly enriched
in PRC2 target genes included: “Behavior”, “Neurological
disorders” and “Psychological disorders”. Our analysis
suggests that PRC2 specifically silences genes involved
in mature brain functions, and that EZH2 is overex-
pressed in undifferentiated cells.
In addition, EZH2 may indirectly activate cell cycle
progression, tumorigenesis and invasion, as shown in
other cancer types [5]. In this regard, the top canonical
pathway activated in EZH2-associated genes was “Mito-
tic roles of Polo-like kinases” (p = 1.83E
-11). As shown
in Figure 3, several EZH2-associated genes are involved
in this pathway, which regulates mitotic entry and DNA
damage-activated checkpoints. Interestingly, Polo
kinases orchestrate thes e l f - r e n e w a lv e r s u s
Figure 1 EZH2 expression in neurological tumors.A ,B :E Z H 2i so v e r e x p r e s s e di nh i g h e rg r ade tumors. C, D: EZH2 overexpression is
associated to poor prognosis in human glioblastoma (Oncomine database).
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Page 3 of 6differentiation decision in neural progenitors, by regulat-
ing the orientation of mitotic spindles [21]. Additional
pathways significantly associated with EZH2 expression
in glioma were “ATM signaling” (p = 2.2E
-6), “G2/M
DNA damage checkpoint” (p = 1.0E
-5)a n d“Sonic
hedgehog signaling” (p = 1.5E
-3). ATM signaling is
involved in DNA repair, while Hedgehog pathway is
essential for neural SCs [5]. Our results are in agree-
ment with in vitro findings, showing that EZH2 is
required for cell cycle control and SC self-renewal [5].
To corroborate our findings, we uploaded PRC2 target
genes and EZH2-associated genes on the Broad Insti-
tute’s Molecular Signature Database http://www.broad-
institute.org/gsea/msigdb/annotate.jsp, and compared
significant overlaps with gene ontology signatures.
EZH2-associated genes were significantly correlated
with “Spindle” (p = 7.6E
-15)a n d“Mitotic cell-cycle”
(p = 8.6E
-15). These categories resembled IPA “Cell
Cycle” sub-categories correlated to EZH2: “Spindle
Checkpoint” (p = 5.3E
-11)a n d“M-phase of eukaryotic
cells” (p = 1.2E
-15)
. PRC2 target genes were associated
to “Trasmission of nerve impulse” (p = 9.1E
-5)a n d
“Axonogenesis” (p = 1.6E
-4). These results corroborate
the hypothesis that PRC2 inhibits neural differentiation-
associated genes in human brain tumors. In addition,
they confirmed the likelihood of a relationship between
EZH2 and mitotic control. Interestingly, EZH2-asso-
ciated genes were also significantly linked to “Up-regu-
lated in doxorubicine resistant cells” (p = 2.2E
-36). This
again highlights the probability of an association
between EZH2 expression and NCSCs, since these are
the cells thought to be responsible for chemotherapeutic
resistance.
In conclusion, we found a correlation between PRC2-
mediated gene silencing and brain tumor progression.
In particular, EZH2 predicts poor prognosis higher
grade. Network analysis revealed that brain tumor cells
overexpressing EZH2 display activation of SC- and cell
cycle-specific pathways, and consistent with this data,
differentiation genes are silenced by PRC2. Our results
obtained on patient gene expression profiles corrobo-
rate in vitro findings, showing that PRC2 is required
f o rN C S Cs e l f - r e n e w a la n dfor glioblastoma tumori-
genesis [12]. Interestingly, 3-dezaneplanocin A
(DZNeP) was shown to disrupt PRC2 activity, thereby
targeting NCSC tumorigenicity [12].. Our findings
Figure 2 Polycomb-related gene expression in glioblastomas.A :P R C 2t a r g e tg e n e sa r es e l e c t i v e l ysilenced in glioblastomas (Oncomine
database). B: Functional analysis comparing EZH2-associated genes (upper column, dark blue) with Polycomb targets (lower column, light blue)
in glioblastomas (IPA software).
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Page 4 of 6suggest that PRC2 is a viable target for human glioma
and possibly for other neurological tumors. Indeed, we
found that EZH2 expression progressively increases
with pediatric tumor grade (figure 1B). Finally, we
identified pathways associated with EZH2 expression
in brain tumors. Along with classical cell cycle and SC
pathways, we found a correlation between EZH2 and
polo-like kinases. Since polo kinases orchestrate sym-
metric division in neural SC [21], this new link is
potentially informative. Polo-like kinase 1 is overex-
pressed in human gliomas [22], and specific inhibitors
of these kinases are being investigated as anticancer
agents [23]. Thus, our results can pave the way to the
rational development of treatments that specifically
target NCSC. These drug regimens may include PRC2
and polo-like kinase inhibitors.
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poor prognosis PC patients. Data were generated through Oncomine
database.
Acknowledgements
This publication has been funded in part with Federal funds from the National
Cancer Institute, National Institutes of Health, under contract No. N01-CO-12400.
This research was supported in part by the Intramural Research Program of the
NIH, National Cancer Institute, Center for Cancer Research. The content of this
publication does not necessarily reflect the views or policies of the Department
of Health and Human Services, nor does mention of trade names, commercial
products, or organizations imply endorsement by the US Government.
Author details
1Cancer Stem Cell Section, Laboratory of Cancer Prevention, National Cancer
Institute at Frederick, Center for Cancer Research, National Cancer Institute,
Frederick, MD, USA.
2Scuola Superiore Sant’Anna, Pisa, Italy.
Authors’ contributions
FC performed the analysis and drafted the manuscript. EH helped in
manuscript drafting and supervised analysis methodology. WLF conceived
the study and helped in manuscript drafting. All authors read and approved
the final manuscript.
Figure 3 Mitotic roles of polo-like kinases. EZH2 associated genes (in red) are highly represented in all mitotic pathways involving polo-like
kinases. Data obtained through IPA software.
Crea et al. Molecular Cancer 2010, 9:265
http://www.molecular-cancer.com/content/9/1/265
Page 5 of 6Competing interests
The authors declare that they have no competing interests.
Received: 5 May 2010 Accepted: 30 September 2010
Published: 30 September 2010
References
1. Kaderali Z, Lamberti-Pasculli M, Rutka JT: The changing epidemiology of
paediatric brain tumours: a review from the Hospital for Sick Children.
Childs Nerv Syst 2009, 25:787-793.
2. MacDonald TJ, Rood BR, Santi MR, Vezina G, Bingaman K, Cogen PH,
Packer RJ: Advances in the diagnosis, molecular genetics, and treatment
of pediatric embryonal CNS tumors. Oncologist 2003, 8:174-186.
3. Ohgaki H, Kleihues P: Epidemiology and etiology of gliomas. Acta
Neuropathologica 2005, 109:93-108.
4. Nagarajan RP, Costello JF: Epigenetic mechanisms in glioblastoma
multiforme. Semin Cancer Biol 2009, 19:188-197.
5. Mathews LA, Crea F, Farrar WL: Epigenetic gene regulation in stem cells
and correlation to cancer. Differentiation 2009, 78:1-17.
6. Vogel T, Stoykova A, Gruss P: Differential expression of polycomb
repression complex 1 (PRC1) members in the developing mouse brain
reveals multiple complexes. Dev Dyn 2006, 235:2574-2585.
7. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM,
Cusimano MD, Dirks PB: Identification of human brain tumour initiating
cells. Nature 2004, 432:396-401.
8. Salmaggi A, Boiardi A, Gelati M, Russo A, Calatozzolo C, Ciusani E,
Sciacca FL, Ottolina A, Parati EA, La Porta C, et al: Glioblastoma-derived
tumorospheres identify a population of tumor stem-like cells with
angiogenic potential and enhanced multidrug resistance phenotype.
Glia 2006, 54:850-860.
9. Fu J, Liu ZG, Liu XM, Chen FR, Shi HL, Pangjesse CS, Ng HK, Chen ZP:
Glioblastoma stem cells resistant to temozolomide-induced autophagy.
Chin Med J (Engl) 2009, 122:1255-1259.
10. Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, Becker N,
Lichter P, Unterberg A, Radlwimmer B, Herold-Mende CC: Stem cell marker
CD133 affects clinical outcome in glioma patients. Clin Cancer Res 2008,
14:123-129.
11. Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB: Tumour-
initiating cells: challenges and opportunities for anticancer drug
discovery. Nat Rev Drug Discov 2009, 8:806-823.
12. Suva ML, Riggi N, Janiszewska M, Radovanovic I, Provero P, Stehle JC,
Baumer K, Le Bitoux MA, Marino D, Cironi L, et al: EZH2 Is Essential for
Glioblastoma Cancer Stem Cell Maintenance. Cancer Res 2009.
13. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, Weinberg RA:
An embryonic stem cell-like gene expression signature in poorly
differentiated aggressive human tumors. Nat Genet 2008, 40:499-507.
14. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K: EZH2 is
downstream of the pRB-E2F pathway, essential for proliferation and
amplified in cancer. Embo J 2003, 22:5323-5335.
15. Hayry V, Tanner M, Blom T, Tynninen O, Roselli A, Ollikainen M, Sariola H,
Wartiovaara K, Nupponen NN: Copy number alterations of the polycomb
gene BMI1 in gliomas. Acta Neuropathol 2008, 116:97-102.
16. Abdouh M, Facchino S, Chatoo W, Balasingam V, Ferreira J, Bernier G: BMI1
sustains human glioblastoma multiforme stem cell renewal. J Neurosci
2009, 29:8884-8896.
17. Chang CJ, Hsu CC, Yung MC, Chen KY, Tzao C, Wu WF, Chou HY, Lee YY,
Lu KH, Chiou SH, Ma HI: Enhanced radiosensitivity and radiation-induced
apoptosis in glioma CD133-positive cells by knockdown of SirT1
expression. Biochem Biophys Res Commun 2009, 380:236-242.
18. Gieni RS, Hendzel MJ: Polycomb group protein gene silencing, non-
coding RNA, stem cells, and cancer. Biochem Cell Biol 2009, 87:711-746.
19. Kohler C, Villar CB: Programming of gene expression by Polycomb group
proteins. Trends Cell Biol 2008, 18:236-243.
20. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D,
Barrette T, Pandey A, Chinnaiyan AM: ONCOMINE: a cancer microarray
database and integrated data-mining platform. Neoplasia 2004, 6:1-6.
21. Wang H, Ouyang Y, Somers WG, Chia W, Lu B: Polo inhibits progenitor
self-renewal and regulates Numb asymmetry by phosphorylating Pon.
Nature 2007, 449:96-100.
22. Dietzmann K, Kirches E, von B, Jachau K, Mawrin C: Increased human polo-
like kinase-1 expression in gliomas. J Neurooncol 2001, 53:1-11.
23. Degenhardt Y, Lampkin T: Targeting Polo-like kinase in cancer therapy.
Clin Cancer Res 16:384-389.
doi:10.1186/1476-4598-9-265
Cite this article as: Crea et al.: Clinical significance of Polycomb gene
expression in brain tumors. Molecular Cancer 2010 9:265.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Crea et al. Molecular Cancer 2010, 9:265
http://www.molecular-cancer.com/content/9/1/265
Page 6 of 6